other material
confidence high
sentiment neutral
materiality 0.35
Tempest Therapeutics gets Nasdaq notice for missing annual meeting; meeting set for Jan 27, 2026
Tempest Therapeutics, Inc.
- Received Nasdaq deficiency letter on Jan 8, 2026 for failing to hold annual meeting within 12 months of fiscal year end Dec 31, 2024.
- Company has 45 calendar days (until Feb 23, 2026) to regain compliance or submit a plan; Nasdaq may grant exception until June 29, 2026.
- Annual meeting already scheduled for Jan 27, 2026; upon holding it, compliance will be regained.